Sanofi is now a key component in the CAC 40 index, which comprises 40 of the most valuable listed companies in France. In the last five years, the Sanofi share price has risen over 22% between July 2017 and July 2022. It reached an all-time high of $106.66 per share in April 2022, which was largely due to its ground-breaking collaboration with Regeneron for Dupixent, a treatment that’s on the verge of obtaining regulatory approval in the US to treat the rare skin condition known as prurigo nodularis.